Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.

An attempt by Roche, a Swiss pharmaceuticals firm, to prevent India’s Natco Pharma from introducing a generic version of a ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

FRANKFURT (Reuters) -Roche's third-quarter sales gained a currency-adjusted 9%, beating market expectations, on higher ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

With only a few days to go before the US presidential elections, new data has been released about the American citizens who ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

The Switzerland market ended marginally down on Wednesday as stocks shed early gains and the index slipped below the flat line in the ...

Swatch Group ended down 2.5%. Novartis, Roche Holding, Kuehne + Nagel, Givaudan, Nestle, Sandoz Group and Swisscom lost 1 to 1.7%. ABB climbed 2.51%. UBS Group gained 1.86%, and Holcim closed up 1.64% ...